Measures of Distinction
Reach
-
In 2016, NewYork-Presbyterian oncology services treated patients from 30 states and 17 countries
Recognition
-
New York-Presbyterian is 1 of 49 National Cancer Institute-designated Comprehensive Cancer Centers in the country
-
NewYork-Presbyterian is rated as Best in Survival, Advanced Technology, and Nurse Staffng by U.S.News & World Report
Research
-
Received over $145 million from the National Institutes of Health and other sponsoring organizations in 2016, including 147 awards from the National Cancer Institute
-
More than 4,700 patients participated in 800+ research studies, including 130 phase 1 and phase 2 trials
Graduate Medical Education
-
237 residents participated in our hematology and oncology residency programs
-
39 fellows participated in our fellowship programs that include:
-
Adult Bone Marrow Transplant
-
Colorectal Surgery
-
Cytopathology
-
Gynecologic Oncology
-
Hematology/Medical Oncology
-
Urologic Oncology
-
Clinical Care
-
Clinicians and Research Scientists
-
544
-
-
Patient Discharges
-
8,600
-
-
Dedicated Oncology Beds
-
137
-
-
Infusion Chairs
-
148
-
-
Infusions
-
83,000
-
-
Gamma Knife Procedures
-
250
-
-
Radiation Therapy Treatments
-
38,000
-
-
Bone Marrow Transplants
-
240
-
-
Multidisciplinary Programs
-
54
-
New Cancer Cases
2016
Source: NewYork-Presbyterian Tumor Registry Cases
NCI Funding
2016
Source: NewYork-Presbyterian